Doctors Stunned By Twin Immunity Gaps

Australia is betting on twins to map why one body shrugs off illness while another struggles.

Story Snapshot

Researchers are recruiting 100 twin pairs to pinpoint genetic and environmental drivers of immune health.
The study aims to explain why similar people respond so differently to infections and treatments.
7NEWS showcased the effort as an Australian-first push to crack “one of medicine’s biggest mysteries”.
Findings could guide faster diagnosis and more precise, lower-cost care for common diseases.

An Australian-first twin study with a practical target: your immune system

Researchers at the Snow Centre for Immune Health and the University of Melbourne’s Twins Research Australia launched an Australian-first twin study to sort how much of immune health comes from genes and how much from life experience. The plan is simple but powerful: enroll 100 pairs of identical and non-identical twins, measure their immune markers, and test how they react to infections and treatments. That contrast lets scientists separate inherited wiring from environmental wear and tear.

7NEWS framed the project as twins helping to crack which diseases are genetic and which are triggered by the environment, highlighting that the results could sharpen personalized treatment for everyone. The broadcast labeled the effort a bid to solve “one of medicine’s biggest mysteries,” and tied it to a broader push on medical research funding. The public message is clear: this is a practical study built to answer everyday questions about risk, resilience, and response to care.

Why twins answer questions single volunteers cannot

Identical twins share almost all their DNA. If their immune systems differ, environment likely drove the split. Non-identical twins share about half, like typical siblings, and add contrast that helps estimate genetic pull versus shared settings like home or school. This classic design remains valuable because it can test environmental explanations while controlling for much of the genetic background. When done well, twin research has shown that most traits land in the middle, not at the extremes of “all genes” or “all environment”.

Large reviews back that middle ground. A Nature Genetics meta-analysis across five decades found an average heritability of about half across traits, which means environment accounts for the other half on average. A review of infant development in JAMA Network Open also found both genetic and environmental roles across early traits. That mix matters for immune health. It hints that smart lifestyle and targeted care can move the needle even when genes set part of the baseline.

What this could change for patients and doctors

The study’s core promise is a clearer map from cause to action. If a marker shows a strong genetic signal, screening can start earlier for high-risk people. If a marker shifts mainly with environment, coaching on sleep, diet, stress, and vaccines can lead care. If a treatment works in one twin but not the other, doctors can test whether genes, microbiome, or past infections drove that split and adapt the plan. That saves time, lowers costs, and reduces side effects by cutting trial and error.

Conservatives often ask for proof that a new program delivers real value. Twin studies answer that call by linking measurement to outcome. They can flag which tests belong in standard care and which add cost without benefit. They also respect personal responsibility. When environment matters, clear guidance lets people act. When genes matter, early knowledge helps families plan and navigate care with fewer surprises.

Guardrails: strong design, careful claims

Every method has limits. Some scholars warn that if twin studies ignore how families choose partners or how twin environments differ, estimates can skew. Others find that core assumptions hold up in many cases, especially when designs adjust for known biases. The best path is simple: preregister plans, measure environments directly, include both identical and non-identical twins, and report uncertainty. The Australian team’s defined recruitment goal and immune focus align with that disciplined approach.

The public should not expect a single magic number that says “genes are 60%.” The smarter win is a blueprint: which immune features lean genetic, which bend with lifestyle, and which treatments work best for each profile. That blueprint can guide steps as small as timing a vaccine or as big as managing autoimmune disease over years. When the results land, the question to ask is not “nature or nurture,” but “what can we do next Monday at the clinic to help this person?”